@article{fdi:010066573,
  title = {{S}trengthening universal {HIV} 'test-and-treat' approaches with social science research},
  author = {{C}amlin, {C}.{S}. and {S}eeley, {J}. and {V}iljoen, {L}. and {V}ernooij, {E}. and {S}imwinga, {M}. and {R}eynolds, {L}. and {R}eis, {R}. and {P}lank, {R}. and {O}rne-{G}liemann, {J}. and {M}c{G}rath, {N}. and {L}armarange, {J}oseph and {H}oddinott, {G}. and {G}etahun, {M}. and {C}harlebois, {E}.{D}. and {B}ond, {V}.},
  editor = {},
  language = {{ENG}},
  abstract = {{S}trengthening universal {HIV} 'test-and-treat' approaches with social science research {T}he recent publication of new {WHO} guidelines, including a call for antiretroviral therapy for everyone diagnosed with {HIV} regardless of {CD}4 þ cell count and preexposure prophylaxis for people at substantial risk of {HIV} infection [1], marks an important moment for taking stock of what will be needed to take biomedical {HIV} prevention approaches to scale, and sustain them. {A}s the author of a recent editorial in {T}he {L}ancet [2] observes, these guidelines are 'welcome but ambitious. [.. .] {N}o studies exist that address how such a strategy can be executed on a global scale' (p. 1420). {W}e, a multidisciplinary group of social scientists working as part of five large-scale 'universal test-and-treat' ({UTT}) trials being implemented across six {A}frican countries, would argue that successful large-scale expansion of treatment and preexposure prophylaxis will require an indepth understanding of the heterogeneous community and health systems' contexts of the rollout.},
  keywords = {{AFRIQUE}},
  booktitle = {},
  journal = {{AIDS}},
  volume = {30},
  numero = {6},
  pages = {969--970},
  ISSN = {0269-9370},
  year = {2016},
  DOI = {10.1097/{QAD}.0000000000001008},
  URL = {https://www.documentation.ird.fr/hor/fdi:010066573},
}